Norwegian Study Can Change the Clinical Practice for Patients with Immune Thrombocytopenia

After seven years of investigation, Professor Walid Ghanima, consultant hematologist and Head of the Department of Research at Østfold Hospital in Norway, is presenting for the first time the results of the PROLONG trial. This study is a two-phase, randomized, placebo-controlled clinical trial designed to optimize the therapeutic response to rituximab by combining it with dexamethasone and subsequent low-dose rituximab maintenance therapy in patients with immune thrombocytopenia (ITP). According to Professor Ghanima, the findings have the potential to change current clinical practice.